Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images
- PMID: 27880938
- PMCID: PMC5352175
- DOI: 10.18632/oncotarget.13476
Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images
Abstract
Purpose: To evaluate the usefulness of surrogate biomarkers as predictors of histopathologic tumor grade and aggressiveness using radiomics data from dual-energy computed tomography (DECT), with the ultimate goal of accomplishing stratification of early-stage lung adenocarcinoma for optimal treatment.
Results: Pathologic grade was divided into grades 1, 2, and 3. Multinomial logistic regression analysis revealed i-uniformity and 97.5th percentile CT attenuation value as independent significant factors to stratify grade 2 or 3 from grade 1. The AUC value calculated from leave-one-out cross-validation procedure for discriminating grades 1, 2, and 3 was 0.9307 (95% CI: 0.8514-1), 0.8610 (95% CI: 0.7547-0.9672), and 0.8394 (95% CI: 0.7045-0.9743), respectively.
Materials and methods: A total of 80 patients with 91 clinically and radiologically suspected stage I or II lung adenocarcinoma were prospectively enrolled. All patients underwent DECT and F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT, followed by surgery. Quantitative CT and PET imaging characteristics were evaluated using a radiomics approach. Significant features for a tumor aggressiveness prediction model were extracted and used to calculate diagnostic performance for predicting all pathologic grades.
Conclusions: Quantitative radiomics values from DECT imaging metrics can help predict pathologic aggressiveness of lung adenocarcinoma.
Keywords: dual energy CT; heterogeneity; lung adenocarcinoma; radiomics; texture analysis.
Conflict of interest statement
All authors contributed to the research, writing and preparation of this manuscript. None of the authors has a potential conflict of interest or financial relationship to disclose.
Figures
References
-
- Zhang J, Wu J, Tan Q, Zhu L, Gao W. Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification. J Thorac Oncol. 2013;8:1196–1202. - PubMed
-
- Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Prognostic impact of histology on early-stage non-small cell lung cancer. Chest. 2011;140:135–145. - PubMed
-
- Tanaka F, Yoneda K. Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC) Surg Today. 2015 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
